Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generics access legislation

This article was originally published in The Tan Sheet

Executive Summary

The "Preserve Access to Affordable Generics Act" (S 316) has been approved by the Senate Judiciary Committee, according to a Feb. 15 announcement. The bill prohibits marketers of proprietary pharmaceuticals from paying generic drug companies to delay introduction of generic versions of drugs. Sen. Herb Kohl, D-Wis., et al. introduced the bill Jan. 17 to "support the purpose and intent of antitrust law by prohibiting anticompetitive agreements and collusion in the pharmaceutical industry," and to "clarify the law to prohibit payments from brand name generic drug manufacturers with the purpose to prevent or delay the entry of competition from generic drugs," according to the bill's text. The legislation also would require FTC to conduct a study on the prevalence in the pharmaceutical industry of anticompetitive agreements or other practices contrary to antitrust laws...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS100228

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel